ePT--the Electronic Newsletter of Pharmaceutical Technology, Feb 7, 2013 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Feb 7, 2013
FDA Lists Guidance Documents Planned for 2013
By Amy Ritter
FDA has released a list of more than 50 guidance documents planned for 2013.
European Commission Investigates J&J and Novartis
By Stephanie Sutton
The European Commission claims that Johnson & Johnson and Novartis may have breached European antitrust rules.
US Pharmacopeial Convention Announces Revised Official Dates for Elemental Impurities Chapters
By Jennifer Markarian
Two general chapters on elemental impurities? limits and procedures are to become official Feb. 1, 2013, with implementation proposed for May 1, 2014.
Shire to Resolve Federal Investigation and Pay $57.5 Million
By Adeline Siew, PhD
Shire announced that it has reached an agreement in principle with the US government to resolve the previously disclosed civil investigation into its sales and marketing practices in the US relating to the company's attention deficit hyperactivity disorder (ADHD) drugs, Adderall XR and Vyvanse as well as the ADHD patch Daytrana.
Pfizer Reports Fourth-Quarter and Full-Year 2012 Financial Results
By Christopher Allen
Pfizer has reported financial results for fourth-quarter and full-year 2012. Fourth-quarter 2012 revenues were $15.1 billion, a decrease of 7% compared with $16.1 billion in the year-ago quarter, which reflects an operational decline of $802 million, or 5%, and the unfavorable impact of foreign exchange of $271 million, or 2%.
GSK Increases Stake in Indian Subsidiary
By Stephanie Sutton
GlaxoSmithKline has increased its stake in its Indian subsidiary, GlaxoSmithKline Consumer Healthcare Ltd, from 43.2% to 72.5%.
Industry Briefs: February 4, 2013
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Regulatory Roundup for the Week of February 4, 2013
The latest news from the pharmaceutical regulatory community.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here